Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

Maria Victoria Mateos; Sophie Rigaudeau; Supratik Basu; Ivan Spicka; Rik Schots; Tomasz Wrobel; Gordon Cook; Meral Beksac; Katharine S. Gries; Anupa Kudva; Brenda Tromp; Rian Van Rampelbergh; Huiling Pei; Susan Wroblewski; Robin Carson; Maria Delioukina; Darrell White

doi:10.1177/10781552221103551

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

Maria Victoria Mateos, Sophie Rigaudeau, Supratik Basu, Ivan Spicka, Rik Schots, Tomasz Wrobel, Gordon Cook, Meral Beksac, Katharine S. Gries, Anupa Kudva, Brenda Tromp, Rian Van Rampelbergh, Huiling Pei, Susan Wroblewski, Robin Carson, Maria Delioukina, Darrell White

科研成果: 期刊稿件 › 文章 › 同行评审

10 引用（Scopus）

源语言	英语
页（从-至）	1172-1177
页数	6
期刊	Journal of Oncology Pharmacy Practice
卷	29
期	5
DOI	https://doi.org/10.1177/10781552221103551
出版状态	已出版 - 7月 2023
已对外发布	是

!!!ASJC Scopus Subject Areas

药学（医学）
肿瘤学

访问文件

10.1177/10781552221103551

其它文件与链接

引用此

Mateos, M. V., Rigaudeau, S., Basu, S., Spicka, I., Schots, R., Wrobel, T., Cook, G., Beksac, M., Gries, K. S., Kudva, A., Tromp, B., Van Rampelbergh, R., Pei, H., Wroblewski, S., Carson, R., Delioukina, M., & White, D. (2023). Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. Journal of Oncology Pharmacy Practice, 29(5), 1172-1177. https://doi.org/10.1177/10781552221103551

Mateos, MV, Rigaudeau, S, Basu, S, Spicka, I, Schots, R, Wrobel, T, Cook, G, Beksac, M, Gries, KS, Kudva, A, Tromp, B, Van Rampelbergh, R, Pei, H, Wroblewski, S, Carson, R, Delioukina, M & White, D 2023, 'Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma', Journal of Oncology Pharmacy Practice, 卷 29, 号码 5, 页码 1172-1177. https://doi.org/10.1177/10781552221103551

@article{c177307a00a245ac8b34e3a3a61bb2dc,

title = "Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma",

keywords = "Multiple myeloma, daratumumab, intravenous, subcutaneous, transplant-ineligible",

author = "Mateos, {Maria Victoria} and Sophie Rigaudeau and Supratik Basu and Ivan Spicka and Rik Schots and Tomasz Wrobel and Gordon Cook and Meral Beksac and Gries, {Katharine S.} and Anupa Kudva and Brenda Tromp and {Van Rampelbergh}, Rian and Huiling Pei and Susan Wroblewski and Robin Carson and Maria Delioukina and Darrell White",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2023",

month = jul,

doi = "10.1177/10781552221103551",

language = "English",

volume = "29",

pages = "1172--1177",

journal = "Journal of Oncology Pharmacy Practice",

issn = "1078-1552",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

AU - Mateos, Maria Victoria

AU - Rigaudeau, Sophie

AU - Basu, Supratik

AU - Spicka, Ivan

AU - Schots, Rik

AU - Wrobel, Tomasz

AU - Cook, Gordon

AU - Beksac, Meral

AU - Gries, Katharine S.

AU - Kudva, Anupa

AU - Tromp, Brenda

AU - Van Rampelbergh, Rian

AU - Pei, Huiling

AU - Wroblewski, Susan

AU - Carson, Robin

AU - Delioukina, Maria

AU - White, Darrell

PY - 2023/7

Y1 - 2023/7

KW - Multiple myeloma

KW - daratumumab

KW - intravenous

KW - subcutaneous

KW - transplant-ineligible

UR - http://www.scopus.com/inward/record.url?scp=85138338424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138338424&partnerID=8YFLogxK

U2 - 10.1177/10781552221103551

DO - 10.1177/10781552221103551

M3 - Article

C2 - 36067063

AN - SCOPUS:85138338424

SN - 1078-1552

VL - 29

SP - 1172

EP - 1177

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

IS - 5

ER -

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

!!!ASJC Scopus Subject Areas

访问文件

其它文件与链接

指纹

引用此